147 related articles for article (PubMed ID: 22391131)
1. High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.
Tzenaki N; Andreou M; Stratigi K; Vergetaki A; Makrigiannakis A; Vanhaesebroeck B; Papakonstanti EA
FASEB J; 2012 Jun; 26(6):2498-508. PubMed ID: 22391131
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages.
Goulielmaki E; Bermudez-Brito M; Andreou M; Tzenaki N; Tzardi M; de Bree E; Tsentelierou E; Makrigiannakis A; Papakonstanti EA
Cell Death Dis; 2018 Jun; 9(6):678. PubMed ID: 29880805
[TBL] [Abstract][Full Text] [Related]
3. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
[TBL] [Abstract][Full Text] [Related]
4. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase phosphorylates the phosphatase and tensin homolog deleted on chromosome 10 under the control of p110δ phosphoinositide-3 kinase.
Tzenaki N; Aivaliotis M; Papakonstanti EA
FASEB J; 2015 Dec; 29(12):4840-52. PubMed ID: 26251180
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
Jiang X; Chen S; Asara JM; Balk SP
J Biol Chem; 2010 May; 285(20):14980-14989. PubMed ID: 20231295
[TBL] [Abstract][Full Text] [Related]
7. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
8. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
9. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
10. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
11. The effect of deleting p110delta on the phenotype and function of PTEN-deficient B cells.
Janas ML; Hodson D; Stamataki Z; Hill S; Welch K; Gambardella L; Trotman LC; Pandolfi PP; Vigorito E; Turner M
J Immunol; 2008 Jan; 180(2):739-46. PubMed ID: 18178811
[TBL] [Abstract][Full Text] [Related]
12. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Zhang C; Xu B; Liu P
Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383
[TBL] [Abstract][Full Text] [Related]
13. Imbalanced PTEN and PI3K Signaling Impairs Class Switch Recombination.
Chen Z; Getahun A; Chen X; Dollin Y; Cambier JC; Wang JH
J Immunol; 2015 Dec; 195(11):5461-5471. PubMed ID: 26500350
[TBL] [Abstract][Full Text] [Related]
14. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
[TBL] [Abstract][Full Text] [Related]
15. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
16. The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.
Sun J; Mohlin S; Lundby A; Kazi JU; Hellman U; Påhlman S; Olsen JV; Rönnstrand L
Oncogene; 2014 Nov; 33(46):5360-9. PubMed ID: 24213578
[TBL] [Abstract][Full Text] [Related]
17. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.
Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H
J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785
[TBL] [Abstract][Full Text] [Related]
18. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
19. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Sawyer C; Sturge J; Bennett DC; O'Hare MJ; Allen WE; Bain J; Jones GE; Vanhaesebroeck B
Cancer Res; 2003 Apr; 63(7):1667-75. PubMed ID: 12670921
[TBL] [Abstract][Full Text] [Related]
20. p110δ PI3 kinase pathway: emerging roles in cancer.
Tzenaki N; Papakonstanti EA
Front Oncol; 2013; 3():40. PubMed ID: 23459844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
